. coli-expressed influenza vaccines.
arge scale manufacturing and eventual commercialisation o
nimal models31. These inherent complications have prevented
reater quantity needed to generate protective immunity i
mmunogenic than egg-derived antigens, with around a 10-fold
onformation31. The resulting processed proteins are less
ing to attain desired purity and to fold to their nativ
ndergo glycosylation33. They therefore need extensive proces
olding, contain impurities (e.g., host-cell proteins), and do no
owever, E. coli-expressed rHA proteins can be subject to mis
ill likely shorten the entire vaccine manufacturing process32
edium-scalepharmaceuticalproductionfacility31.Thisapproac
ould yield up to half a billion doses of vaccine per month in
umberofbioreactors31.Theauthorsprojectedthatthestrateg
ields of rHA (200mg/L of purified HA protein) using a minima
. coli expression system has been shown to generate a hig
esponses in healthy adults with favourable tolerability30. Th
accine developed using this E. coli platform elicited immun
odels29.InPhase1clinicalevaluation,aprototypicquadrivalen
licited strong and protective antibody responses in mous
almonella typhimurium flagellin type 229. The resultant vaccine
rotein genetically fused with the Toll-like receptor 5 agonist
nvolved expression of the globular head domain of the H
anufactured using an Escherichia coli fermentation system
andidate recombinant influenza vaccines to be successfull
sed for the manufacture of rHA vaccine antigens. The firs
oth prokaryotic and eukaryotic expression systems have bee